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Background:  The present study was designed to evaluate the efficacy of the wearable cardioverter-defibrillator (WCD) for the prevention of 
sudden cardiac death in patients with congenital heart disease (CHD) and inherited arrhythmias (IA).
Methods:  The study population comprised 162 patients with CHD (n=43) and IA (n=119) who were prospectively followed up in a nationwide 
registry from 2005-2010. Mortality rates were compared using Kaplan-Meier survival analysis.
Results:  Mean age of study patients was 38 ± 27 years. CHD patients had higher frequency of left ventricular dysfunction (<50%) than IA patients 
(63% vs. 16%, respectively; p<0.01). The predominant indication for WCD was pending genetic testing in the IA group, and transplant listing in the 
CHD group. Compliance with the WCD was similar in the 2 groups (91%). WCD shocks successfully terminated 3 ventricular tachyarrhytmias in IA 
patients during an average of 47 days of therapy (corresponding to an event rate of 23 appropriate WCD shocks per 100 patient years), whereas no 
arrhythmias occurred in CHD patients during an average of 94 days. No patients died while actively wearing the WCD. At 1-year of follow-up mortality 
rates were significantly higher among CHD patients compared with IA patients (Fig. 1).
Conclusion: Our data suggest that WCD can be safely used in high-risk adult patients with IA and CHD. Patients with IA show a higher rate of 
ventricular tachyarrhythmias during therapy, but exhibit significantly lower long-term mortality rates. 
